Incremental costs (NZ$) | Incremental QALYs gained | Incremental cost-effectiveness ratio | |||||||
---|---|---|---|---|---|---|---|---|---|
Total | Māori | Non-Māori | Total | Māori | Non-Māori | Total | Māori | Non-Māori | |
Main modela | $119 | $138 | $117 | 0.006 | 0.014 | 0.005 | $20,600 | $10,100 | $24,700 |
Equity analysis—equal life expectancy and background morbidity for Māori and non-Māori | $121 | $155 | $117 | 0.006 | 0.019 | 0.005 | $18,800 | $8,200 | $24,700 |
Equal coverage—coverage in Māori was set to the same as non-Māori (84%) | $120 | $143 | $117 | 0.006 | 0.014 | 0.005 | $20,400 | $10,000 | $24,700 |
Low coverage—coverage in Māori of 45% and non-Māori of 58% akin to a NZ colorectal screening pilot | $93 | $95 | $93 | 0.004 | 0.008 | 0.003 | $24,500 | $12,400 | $28,400 |
Equal eradication—triple therapy was increased to be 95% effective (e.g. levofloxacin) | $118 | $132 | $116 | 0.006 | 0.015 | 0.005 | $19,600 | $8,900 | $24,200 |
No retest to ensure effective eradication | $101 | $107 | $100 | 0.005 | 0.010 | 0.004 | $20,600 | $10,900 | $23,600 |
Follow-up for 15 years (rather than over a lifetime) | $118 | $132 | $116 | 0.003 | 0.008 | 0.003 | $35,600 | $16,000 | $44,000 |
The effect size in the youngest age groups is greater (<40yo, RR of 0.50) | $119 | $139 | $117 | 0.006 | 0.016 | 0.005 | $18,400 | $8,700 | $22,500 |
The complication rate for CDI was increased from 80 to 800 per 100,000 | $124 | $146 | $121 | 0.006 | 0.014 | 0.005 | $21,400 | $10,700 | $25,600 |
6% discounting QALYs and costs | $112 | $118 | $111 | 0.003 | 0.007 | 0.002 | $39,200 | $17,300 | $48,200 |
0% discounting QALYs and costs | $151 | $225 | $141 | 0.015 | 0.034 | 0.012 | $10,300 | $6,600 | $11,700 |
No unrelated health system costs | $82 | $52 | $86 | 0.006 | 0.014 | 0.005 | $14,200 | $3,800 | $18,300 |
No pYLDs (background morbidity) | $119 | $138 | $117 | 0.008 | 0.021 | 0.007 | $14,300 | $6,700 | $17,500 |